List of Excipients in Branded Drug IOPIDINE 1%

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Harrow Eye LLC	IOPIDINE 1%	apraclonidine hydrochloride ophthalmic solution	82667-200	BENZALKONIUM CHLORIDE
Harrow Eye LLC	IOPIDINE 1%	apraclonidine hydrochloride ophthalmic solution	82667-200	HYDROCHLORIC ACID
Harrow Eye LLC	IOPIDINE 1%	apraclonidine hydrochloride ophthalmic solution	82667-200	SODIUM ACETATE
Harrow Eye LLC	IOPIDINE 1%	apraclonidine hydrochloride ophthalmic solution	82667-200	SODIUM CHLORIDE

Iopidine 1% Excipient Strategy and Commercial Opportunities

Last updated: October 30, 2026

Iopidine 1% is apraclonidine hydrochloride ophthalmic solution, an older small-molecule glaucoma product used to reduce intraocular pressure before and after laser procedures. Its commercial opportunity is primarily generic substitution, preservative-free reformulation, improved tolerability, and hospital or ambulatory-surgery supply. The formulation has limited composition-of-matter protection and no biosimilar barrier.

The core product is an aqueous, preserved ophthalmic solution containing apraclonidine hydrochloride 1%, equivalent to 10 mg/mL apraclonidine. The reference formulation uses benzalkonium chloride, sodium acetate, sodium chloride, purified water, and pH adjustment agents.[1]

What is Iopidine 1% and how is it regulated?

Iopidine 1% is the brand name for apraclonidine hydrochloride ophthalmic solution. Apraclonidine is an alpha-adrenergic agonist that lowers aqueous humor production and reduces intraocular pressure.

Attribute	Iopidine 1%
Active ingredient	Apraclonidine hydrochloride
Strength	1%, equivalent to 10 mg/mL apraclonidine
Dosage form	Sterile ophthalmic solution
Route	Topical ocular
Reference NDA	NDA 019658
Original sponsor	Alcon Laboratories
FDA approval	1988
Primary use	Short-term reduction of elevated intraocular pressure
Typical procedural use	Before and after laser trabeculoplasty or iridotomy
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable
Main substitute	Generic apraclonidine ophthalmic solution

Apraclonidine is generally used for short-duration pressure reduction rather than chronic maintenance therapy. The FDA label warns that clinical response can decline with continued use, and ocular allergy or contact dermatitis can limit treatment.[1]

What excipients are used in Iopidine 1%?

The Iopidine 1% formulation uses a conventional buffered, isotonic ophthalmic system.

Excipient or component	Formulation role
Benzalkonium chloride, 0.01%	Preservative
Sodium acetate	Buffering and pH control
Sodium chloride	Tonicity adjustment
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Purified water	Vehicle

The labeled formulation targets an ophthalmic-compatible pH and osmolality. The formulation is designed for multidose use, which explains the inclusion of benzalkonium chloride.[1]

What is the strategic function of benzalkonium chloride?

Benzalkonium chloride, commonly called BAK, protects a multidose container from microbial contamination. It is effective at low concentrations and widely used in ophthalmic products, but repeated exposure can contribute to ocular-surface irritation, tear-film disruption, and epithelial toxicity.

For Iopidine 1%, BAK creates a clear reformulation opportunity. Apraclonidine itself is associated with ocular allergy and eyelid or conjunctival reactions. A BAK-free product would not eliminate active-ingredient hypersensitivity, but it could reduce preservative-related tolerability concerns and create differentiation against standard generic solutions.

What commercial opportunities exist for Iopidine 1% excipients?

The strongest opportunities are formulation-based rather than molecule-based.

1. Preservative-free unit-dose Iopidine

A preservative-free, single-use product could target:

• Patients with ocular-surface disease
• Patients receiving multiple topical glaucoma products
• Ambulatory surgery centers
• Hospital ophthalmology departments
• Short-term perioperative dosing
• Patients with documented BAK sensitivity

A unit-dose container removes the need for antimicrobial preservation. It also supports a clean-label positioning strategy, although unit-dose packaging increases manufacturing, filling, packaging, and logistics costs.

A preservative-free formulation would likely require a 505(b)(2) strategy if its excipient system or container presentation differs materially from the reference product. The sponsor would need to establish sterility, stability, extractables and leachables, container closure integrity, dose uniformity, and comparative ocular tolerability.

2. BAK-free multidose packaging

A multidose BAK-free presentation could use a validated preservative-free multidose dispensing system or a low-sorption, one-way valve container. This format may reduce per-dose packaging costs compared with unit-dose vials while maintaining microbial protection through the container system.

The regulatory burden is higher than for a conventional preserved bottle. The sponsor must demonstrate that the dispensing system maintains sterility through the labeled in-use period. The device and formulation may become inseparable from the product’s regulatory strategy.

3. Improved ocular comfort

A reformulation could optimize:

• Buffer species
• pH
• Osmolality
• Ionic strength
• Surface tension
• Drop volume
• Viscosity
• Container tip geometry

The existing sodium acetate and sodium chloride system is simple and economical. The main technical challenge is avoiding a formulation that improves comfort but changes apraclonidine stability, ocular absorption, or drop delivery.

A lower-viscosity formulation may improve administration and reduce blurred vision. A modest viscosity increase could extend ocular residence time, but it may also increase visual disturbance, residue, and manufacturing complexity.

4. Reduced drop volume

Most ophthalmic bottles deliver a drop larger than the conjunctival sac can retain. A controlled-drop container or low-volume nozzle could reduce waste and systemic absorption.

This opportunity has commercial value in procedural settings, where dosing may involve multiple administrations within a short period. A smaller drop could also support a lower total exposure while preserving the intended ocular effect. The sponsor would need comparative bioavailability or pharmacodynamic evidence and must ensure that the product remains easy to administer.

5. Improved packaging and adherence

Packaging improvements could include:

• Tamper-evident sterile unit-dose packs
• Color-coded caps for procedural use
• Multi-pack cartons for laser centers
• Integrated dose counters
• Preservative-free multidose dispensers
• Packaging compatible with hospital automated dispensing systems

Packaging claims are generally easier to defend when they relate to measurable delivery, sterility, stability, or usability outcomes. Broad claims based only on convenience are less likely to create durable market protection.

What patents protect Iopidine 1%?

The principal commercial product is an old small-molecule formulation. Composition-of-matter protection for apraclonidine is not a current competitive barrier in the United States.

Protection category	Current commercial relevance
Apraclonidine composition of matter	Expired or no longer material to U.S. generic entry
Original ophthalmic formulation	Historical protection; no significant current barrier
Method of use	Limited value because the approved clinical use is established
Preserved solution	Vulnerable to conventional ANDA competition
Preservative-free formulation	Potential new protection if technically differentiated
Container-closure system	Potential device or combination-product protection
Manufacturing process	Potential trade-secret and process-patent value
Regulatory exclusivity	No meaningful new-drug exclusivity expected for the legacy product

The FDA Orange Book remains the controlling source for current U.S. patent and exclusivity listings. The Orange Book entry for an old Iopidine product should be reviewed against the current edition when making a launch or litigation decision.[2]

What formulations could support new patent claims?

A defensible formulation patent would need more than a new excipient list. Potential claim themes include:

1. A preservative-free apraclonidine solution with defined pH and osmolality ranges.
2. A formulation with improved chemical stability over a specified shelf life.
3. A low-irritation formulation supported by comparative clinical or ex vivo data.
4. A multidose sterile dispensing system that prevents microbial ingress.
5. A formulation with a defined drop size or reduced delivered volume.
6. A combination of apraclonidine with a specific buffer and stabilizer system.
7. A low-extractables formulation and container combination.
8. A formulation that reduces degradation products under light or elevated-temperature conditions.

Patent strength would depend on unexpected results. A claim covering apraclonidine, water, sodium chloride, and a conventional buffer would face substantial obviousness risk because those components are standard in ophthalmic products.

When does Iopidine 1% lose exclusivity?

Iopidine has already passed its principal exclusivity period. The commercial market is therefore governed by generic approval, manufacturing economics, supply reliability, and formulation differentiation rather than by a future brand patent cliff.

Milestone	Commercial implication
Original approval in 1988	Established the reference product
New-drug exclusivity	Expired
Original patent protection	Expired or commercially immaterial
Current market	Generic substitution and legacy brand supply
New entry pathway	ANDA for equivalent product or 505(b)(2) for differentiated formulation
Biosimilar exposure	None

The absence of meaningful current exclusivity does not guarantee immediate generic entry. Sterile ophthalmic manufacturing, container qualification, facility compliance, and supply economics can restrict the number of viable suppliers.

What is the Orange Book status of Iopidine 1%?

The Orange Book is relevant for identifying the reference listed drug, approved dosage form, strength, therapeutic equivalence codes, listed patents, and exclusivity. For a legacy product such as Iopidine 1%, the practical questions are:

• Which NDA is the reference listed drug?
• Is the specific 1% ophthalmic solution currently listed as marketed?
• Which ANDAs have therapeutic-equivalence designations?
• Are any patents or regulatory exclusivities still listed?
• Are there product discontinuation or supply-status changes?

A generic sponsor seeking a conventional apraclonidine ophthalmic solution would generally pursue an ANDA referencing the listed drug. The product must match the reference drug in active ingredient, dosage form, route, strength, and key pharmaceutical characteristics. Inactive ingredients may differ within FDA limits, but the formulation cannot create a new safety or efficacy question that would require a different pathway.[3]

Which companies are challenging Iopidine 1%?

The relevant competitive group consists of generic ophthalmic manufacturers rather than biosimilar developers. Potential competitors include established sterile ophthalmic companies, specialty generic manufacturers, and contract manufacturers with aseptic fill-finish capacity.

The competitive landscape should be evaluated by:

• ANDA approval status
• Therapeutic-equivalence rating
• Current commercial availability
• FDA manufacturing history
• Backorder frequency
• Bottle and unit-dose presentation
• Preserved versus preservative-free formulation
• Wholesale acquisition cost
• Hospital contracting position

No biosimilar challenge is relevant because apraclonidine is a chemically synthesized small molecule. A company entering with a standard formulation would compete primarily on price and supply. A company entering with a BAK-free or unit-dose product could compete on tolerability, packaging, and institutional procurement.

What Paragraph IV challenges affect Iopidine 1%?

A conventional Iopidine 1% ANDA applicant would face a limited Paragraph IV risk profile if no current Orange Book patent blocks entry. A Paragraph IV certification is required when the applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. If no relevant patent is listed, the applicant may rely on a different certification pathway.

For a new differentiated formulation, the patent strategy changes. A sponsor could seek patents covering the improved formulation or dispensing system, then list eligible patents in the Orange Book if the statutory requirements are met. The commercial value would depend on whether generic applicants can design around the claims.

A formulation patent should not rely on the brand name or on broad claims to apraclonidine solution. It should define measurable technical features, such as excipient concentrations, pH, osmolality, preservative absence, container performance, stability, or microbial protection.

What patent litigation affects apraclonidine ophthalmic products?

The principal litigation risk is unlikely to involve the expired original molecule. Future disputes would more likely concern:

• A new preservative-free formulation
• A proprietary multidose container
• A low-volume dispensing system
• A stability-enhancing excipient combination
• Orange Book listing and patent-certification strategy
• Trade dress or product substitution
• Manufacturing know-how and contract-manufacturing obligations

Settlement agreements would be commercially important only if a new formulation patent generated a meaningful barrier. For the legacy preserved solution, price competition and supply execution are more important than branded patent litigation.

How strong is the Iopidine 1% patent estate?

The legacy patent estate is weak for current commercial protection. The stronger opportunity is to create a new, evidence-supported estate around formulation, delivery, and manufacturing.

Asset	Patent strength
Original apraclonidine molecule	Low current value
Conventional preserved solution	Low
Standard sodium acetate/sodium chloride system	Low
BAK-free formulation	Moderate if supported by unexpected results
Unit-dose presentation	Moderate, often dependent on packaging claims
Sterile multidose container	Moderate to strong if technically novel
Drop-size control	Moderate if linked to measurable clinical or delivery benefit
Manufacturing process	Moderate; trade-secret protection may be stronger
Hospital-specific packaging	Low to moderate

Trade secrets may protect aseptic processing parameters, filtration conditions, filling controls, container handling, and stability-improvement methods more effectively than patents if the information cannot be reverse-engineered.

What generic launch risks exist for Iopidine 1%?

The main launch risks are operational and regulatory.

Sterile manufacturing risk

Ophthalmic solutions require validated aseptic processing or terminal sterilization compatible with the active ingredient and container. A sponsor must control particulate matter, bioburden, sterility, endotoxin, fill volume, container closure, and preservative effectiveness where applicable.

Formulation risk

Apraclonidine formulations must maintain chemical stability and acceptable ocular tolerability. Changes in pH, buffer concentration, or ionic strength can affect comfort, degradation, and delivery.

Supply risk

The opportunity is more attractive when incumbent supply is inconsistent. However, sterile ophthalmic manufacturing shortages can affect both new entrants and existing suppliers. A dual-source API and qualified backup fill-finish site can materially improve launch resilience.

Substitution risk

A conventional generic solution faces rapid price erosion if multiple therapeutically equivalent products are available. A preservative-free product may avoid direct price comparison but must justify its higher cost through formulary, patient, or procedural value.

Clinical-tolerability risk

Apraclonidine can cause allergic reactions and tachyphylaxis independent of the excipient system. Marketing claims should distinguish preservative-related tolerability from active-ingredient hypersensitivity.

How does Iopidine 1% compare with other glaucoma products?

Product category	Main advantage	Main limitation	Opportunity relative to Iopidine
Apraclonidine 1%	Rapid short-term pressure reduction	Allergy and tachyphylaxis	Procedural and perioperative use
Brimonidine	Chronic glaucoma use	Ocular allergy and systemic effects	Larger chronic-use market
Timolol	Low-cost pressure reduction	Cardiopulmonary contraindications	Different safety profile
Prostaglandin analogs	Strong chronic efficacy	Ocular surface and cosmetic effects	Less directly substitutable
Carbonic anhydrase inhibitors	Established pressure reduction	Dosing burden and tolerability	Different formulation opportunity
Fixed combinations	Reduced bottle burden	More complex regulatory and formulation profile	Higher development cost

Iopidine is less attractive as a chronic glaucoma product than brimonidine or prostaglandin analogs. Its better commercial positioning is short-term procedural use, rescue pressure reduction, and institutional supply.

What licensing deals could support an Iopidine 1% product?

Potential licensing structures include:

• An ANDA acquisition from a company with an approved sterile ophthalmic facility
• A co-development agreement for a preservative-free formulation
• A container-technology license for preservative-free multidose delivery
• A contract manufacturing and supply agreement
• A regional commercialization license for hospital or ophthalmology channels
• A formulation patent license paired with regulatory services

The most valuable partner is likely to have established ophthalmic manufacturing and regulatory infrastructure rather than only a patent portfolio. A technically novel formulation without reliable sterile fill-finish capacity has limited commercial value.

What geographic opportunities exist for apraclonidine ophthalmic products?

The United States offers a mature generic market with established FDA pathways. Europe and other regulated markets may offer opportunities for preservative-free presentations, but local requirements for multidose preservation, container systems, and clinical justification differ.

Commercial opportunity is strongest where:

• Laser ophthalmology volume is high
• Preservative-free products receive formulary preference
• Hospital procurement rewards supply reliability
• Generic competition is limited
• Existing products have recurring shortages
• Unit-dose packaging has procedural value

A global program should not assume that the U.S. formulation, label, package, and preservative strategy can be transferred without modification.

Key Takeaways

• Iopidine 1% is apraclonidine hydrochloride 10 mg/mL in a preserved aqueous ophthalmic solution.
• Its original molecule and conventional formulation do not provide a strong current U.S. exclusivity barrier.
• The principal excipient opportunity is a BAK-free or preservative-free presentation.
• Unit-dose packaging and validated preservative-free multidose systems offer the clearest differentiation.
• A conventional ANDA would compete mainly on price, quality, and supply reliability.
• A 505(b)(2) strategy may be appropriate for a materially different formulation or delivery system.
• New patent value would depend on measurable technical improvements and unexpected results.
• Apraclonidine has no biosimilar risk because it is a small-molecule drug.
• The best commercial channels are ambulatory surgery centers, hospitals, laser clinics, and patients requiring short-term pressure reduction.
• Manufacturing, container closure, sterility, and supply continuity are more important launch barriers than the legacy Iopidine patent estate.

FAQs

Is Iopidine 1% still protected by a U.S. patent?

The original Iopidine molecule and conventional ophthalmic formulation are legacy assets. Current commercial protection is not expected to depend on the original patent estate. The current FDA Orange Book should be used to confirm any remaining listed patent or exclusivity entry.

Can a company launch preservative-free apraclonidine without conducting full clinical trials?

Possibly, depending on the formulation and regulatory pathway. A formulation that raises new safety or efficacy questions may require a 505(b)(2) application and additional clinical or comparative studies. A conventional equivalent product may qualify for an ANDA.

Is benzalkonium chloride necessary in an apraclonidine multidose bottle?

BAK is not inherently required if the multidose container provides validated microbial protection or another preservative system is used. The alternative system must demonstrate sterility maintenance, preservative effectiveness where applicable, compatibility, and stability.

Does apraclonidine have biosimilar competition?

No. Apraclonidine is a chemically synthesized small molecule. Competition proceeds through generic drug pathways, principally an ANDA or, for differentiated formulations, a 505(b)(2) application.

What is the most attractive commercial reformulation of Iopidine 1%?

A preservative-free product in unit-dose packaging is the clearest opportunity. A validated preservative-free multidose system may offer better economics but carries greater device, sterility, and regulatory complexity.

References

1. U.S. Food and Drug Administration. (2017). Iopidine (apraclonidine hydrochloride ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). ANDA submissions: Content and format of an abbreviated new drug application. FDA guidance.